1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2015

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 154 pages

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2015’, provides an overview of the Squamous Non-Small Cell Lung Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2015
Table of Contents
Introduction 8
Global Markets Direct Report Coverage 8
Squamous Non-Small Cell Lung Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Squamous Non-Small Cell Lung Cancer - Overview 10
Pipeline Products for Squamous Non-Small Cell Lung Cancer - Comparative Analysis 11
Squamous Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 12
Squamous Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 15
Squamous Non-Small Cell Lung Cancer - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Squamous Non-Small Cell Lung Cancer - Products under Development by Companies 19
Squamous Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes 21
Squamous Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
Advenchen Laboratories, LLC 23
Ascenta Therapeutics, Inc. 24
AstraZeneca PLC 25
Bayer AG 26
Boehringer Ingelheim GmbH 27
Bristol-Myers Squibb Company 28
Celgene Corporation 29
Eisai Co., Ltd. 30
Eli Lilly and Company 31
F. Hoffmann-La Roche Ltd. 32
Five Prime Therapeutics, Inc. 33
Genentech, Inc. 34
Johnson and Johnson 35
Novartis AG 36
Oncogenex Pharmaceuticals, Inc. 37
Ono Pharmaceutical Co., Ltd. 38
Vertex Pharmaceuticals Incorporated 39
Squamous Non-Small Cell Lung Cancer - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
ABT-414 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
apatorsen - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
AT-406 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
AZD-8186 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
BAY-1163877 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
BMS-833923 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
BMS-906024 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
buparlisib hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
FP-1039 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
ipilimumab - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
JNJ-42756493 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
lenvatinib - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
lucitanib - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
lumretuzumab - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
LY-2606368 - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
LY-3023414 - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
necitumumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
nintedanib - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
nivolumab (recombinant) - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
paclitaxel albumin bound - Drug Profile 98
Product Description 98
Mechanism of Action 98
RandD Progress 98
pictilisib - Drug Profile 102
Product Description 102
Mechanism of Action 102
RandD Progress 102
Small Molecule to Inhibit TWIST1 for Non-Small Cell Lung Cancer - Drug Profile 104
Product Description 104
Mechanism of Action 104
RandD Progress 104
veliparib - Drug Profile 105
Product Description 105
Mechanism of Action 105
RandD Progress 105
VX-970 - Drug Profile 108
Product Description 108
Mechanism of Action 108
RandD Progress 108
Squamous Non-Small Cell Lung Cancer - Recent Pipeline Updates 109
Squamous Non-Small Cell Lung Cancer - Dormant Projects 145
Squamous Non-Small Cell Lung Cancer - Discontinued Products 146
Squamous Non-Small Cell Lung Cancer - Product Development Milestones 147
Featured News and Press Releases 147
Jan 11, 2015: CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early 147
Oct 30, 2014: Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology 147
Oct 23, 2014: Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer 149
Jul 01, 2014: OncoGenex Announces Cedar Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment 150
May 14, 2014: Clovis Oncology Announces Clinical Data Of Lucitanib to Be Presented at 2014 ASCO Annual Meeting 150
Aug 13, 2013: Eli Lilly and Company's Phase III study of necitumumab meets primary endpoint 151
Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies 151
May 23, 2013: OncoGenex Pharma Announces Plans For Initiation Of Cedar Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer 152
Appendix 153
Methodology 153
Coverage 153
Secondary Research 153
Primary Research 153
Expert Panel Validation 153
Contact Us 154
Disclaimer 154

List of Tables

Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2015 10
Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Squamous Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2015 22
Squamous Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 23
Squamous Non-Small Cell Lung Cancer - Pipeline by Ascenta Therapeutics, Inc., H1 2015 24
Squamous Non-Small Cell Lung Cancer - Pipeline by AstraZeneca PLC, H1 2015 25
Squamous Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2015 26
Squamous Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 27
Squamous Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 28
Squamous Non-Small Cell Lung Cancer - Pipeline by Celgene Corporation, H1 2015 29
Squamous Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H1 2015 30
Squamous Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2015 31
Squamous Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 32
Squamous Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2015 33
Squamous Non-Small Cell Lung Cancer - Pipeline by Genentech, Inc., H1 2015 34
Squamous Non-Small Cell Lung Cancer - Pipeline by Johnson and Johnson, H1 2015 35
Squamous Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H1 2015 36
Squamous Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 37
Squamous Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 38
Squamous Non-Small Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 39
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 42
Number of Products by Stage and Mechanism of Action, H1 2015 45
Number of Products by Stage and Route of Administration, H1 2015 47
Number of Products by Stage and Molecule Type, H1 2015 49
Squamous Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2015 109
Squamous Non-Small Cell Lung Cancer - Dormant Projects, H1 2015 145
Squamous Non-Small Cell Lung Cancer - Discontinued Products, H1 2015 146

List of Figures

Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2015 10
Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Top 10 Targets, H1 2015 41
Number of Products by Stage and Top 10 Targets, H1 2015 41
Number of Products by Top 10 Mechanism of Actions, H1 2015 44
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44
Number of Products by Top 10 Routes of Administration, H1 2015 46
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46
Number of Products by Top 10 Molecule Types, H1 2015 48
Number of Products by Stage and Top 10 Molecule Types, H1 2015 48

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

Prescription barriers hurt 5 of the 9 brands we surveyed. Is your brand losing market share? In the EU5, one of the most prescribed NSCLC drugs is stuck in 2nd place due to the biggest barrier-related ...

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the UK

  • November 2016
    10 pages
  • Cancer  

  • United Kingdom  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.